A vision for growth, shaped by experience.

Ms. Androski joined Arbutus in February 2025 as President and CEO and Chairperson of the Board. Ms. Androski, an MIT-trained biologist, has nearly 30 years of experience in biotechnology, law, and academia. She has served in a variety of roles at Roivant including President and CEO of Roivant Social Ventures and Vice President, Head of Acquisitions. At Roivant she built and led the team responsible for the in-licensing or acquisition of more than 30 therapeutic programs, resulting in the launch and incubation of 16 subsidiary biotechs and several successful IPOs. Prior to joining Roivant, Ms. Androski spent more than a decade as a trial lawyer, including as an Assistant U.S. Attorney in the Eastern District of Virginia. Earlier in her career, Ms. Androski was a strategy consultant advising Fortune 100 clients on merger integration and other business challenges. She is currently a member of the board of directors at Eloxx Pharma. Ms. Androski holds two Bachelor of Science degrees from the Massachusetts Institute of Technology, JD and MBA degrees from The University of Chicago, is a registered Patent Lawyer and a CFA charterholder. She serves as a Trustee of MIT, where she Chairs the Visiting Committee for the Department of Chemistry, and sits on the Visiting Committees for the Department of Biology, the Department of Humanities, Sponsored Research, and the Advisory Board of the MIT Press.

Mr. Sung joined Arbutus in April 2025 as General Counsel and brings over 20 years of legal experience representing and advising companies on corporate matters, intellectual property, compliance, contracting, litigation and employment issues. Mr. Sung, an MIT-trained chemist, has conducted multiple life sciences transactions including over $24B of M&A deals and licensing and collaboration agreements exceeding $4B in potential payments. Prior to Arbutus, Mr. Sung served as General Counsel of Harmonix Music Systems, Inc. for several years, and most recently worked at Epic Games, Inc. following Epic’s acquisition of Harmonix. Before moving in-house, Mr. Sung was a Life Sciences Corporate Associate at Ropes & Gray LLP and worked as a Senior Consultant in the Life Sciences practice at Cap Gemini Ernst & Young. Mr. Sung earned his J.D. from Harvard Law School and his B.S in Chemistry from Massachusetts Institute of Technology.

Mr. Nguyen joined Arbutus in March 2025 as Chief Financial Officer. Mr. Nguyen has more than 15 years of strategic finance experience with biopharma companies in various stages of development. Over his career, he raised $2B in capital and successfully closed a partnership deal with AstraZeneca valued at $2.2B. Most recently, Tuan was CFO at Kinevant Sciences where he led finance and operation functions and implemented structure and processes within the organization to fuel growth opportunities. Prior to that he held various senior finance leadership roles at Adverum Biotechnologies, Intarcia Therapeutics, Fibrogen, and UCB. Tuan earned his MBA with dual concentration in Finance and Entrepreneurship, Innovation, & Change from Emory University and BS in Finance from Louisiana Tech University.